Characterization of TBX3-Null ESCs
(A) BrdU-FACS of TBX3ven/ven and TBX3+/+ ESC lines. Gate at y axis, apoptotic cells; lower left circle, G0/G1 population; lower right circle, G2/M population; upper big gate, S phase.
(B) Quantification of BrdU incorporation summarized from three TBX3ven/ven and a TBX3+/+ ESC line. n = 3 (three individual clones). DAPI-based cell-cycle analysis revealed no difference between TBX3ven/ven and TBX3+/+ ESCs (data not shown).
(C) Quantified AP+ colonies after removing individual LIF/2i components. N2B27 backbone medium. n = 3, for two independent clones with duplicate technical replicates.
(D) Co-culture strategy to compare self-renewal capacity of TBX3+/+ and TBX3ven/ven mESC under LIF/2i. Analysis at start (P0) and end of experiment (P3) for venus expression via FACS is shown. n = 3, for two independent clones with duplicate technical replicates.
(E) Quantification of cell populations from (D) after three passages.
(F) Phase images of TBX3ven/ven and TBX3+/+ mESC at 0 hr, 24 hr, 48 hr, and 72 hr after withdrawal of LIF and 2i. Delayed differentiation of TBX3ven/ven as evident by preserved ESC morphology. The scale bars represent 20 μm.
(G–I) mRNA levels of pluripotency markers (Oct3/4, Sox2, and Nanog), early endodermal markers (Foxa2, Eomes, and Hnf4a), T (brachyury) mesodermal, and Pax6 as ectodermal marker in TBX3+/+ and TBX3ven/ven mESC at respective time points of LIF/2i withdrawal. Two clones per genotype are shown.
Two independent experiments performed with triplicate technical replicates are shown. See also .